Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate
When evaluating non-prescription interventions, the patient data was highly illuminating
In 2018, Jonathan published an article in the peer reviewed Journal of Nicotine and Tobacco Research that explored the history of the warnings on tobacco products and the tobacco industrys role in crafting and manipulating current warning labels
During your visit, a MOBO provider will assess your weight loss and wellness goals